Camelot Portfolios LLC Invests $553,000 in IQVIA Holdings Inc. $IQV

Camelot Portfolios LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel.com reports. The firm purchased 3,510 shares of the medical research company’s stock, valued at approximately $553,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Sowell Financial Services LLC acquired a new stake in IQVIA during the first quarter valued at approximately $305,000. Mather Group LLC. raised its position in shares of IQVIA by 83.5% during the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after purchasing an additional 350 shares during the period. Private Advisor Group LLC raised its position in shares of IQVIA by 11.6% during the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares during the period. Park Avenue Securities LLC raised its position in shares of IQVIA by 40.4% during the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after purchasing an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of IQVIA by 34.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after purchasing an additional 3,398 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.6%

Shares of IQV opened at $179.51 on Friday. The company has a market capitalization of $30.52 billion, a P/E ratio of 25.98, a PEG ratio of 1.97 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $237.34. The business’s 50 day simple moving average is $187.01 and its 200-day simple moving average is $167.15.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Robert W. Baird raised their target price on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Mizuho raised their target price on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Barclays raised their target price on IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Finally, UBS Group lifted their price objective on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.